Andrew Reardon sold $1.0M of LGND
CLO & Secretary at LIGAND PHARMACEUTICALS INC. 5,000 shares at an average of $206.35, traded Mar 4, 2026, filed Mar 6, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.0M at market
- +5Share of holdings soldSold 12% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.1%, 3m +17.4%, 6m +41.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002001011-26-000024, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | MOption exercise Common Stock10b5-1 | +5,000 | $52.27 | $261k | 41,869 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $197.70 | $20k | 41,769 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $199.01 | $20k | 41,669 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -207 | $199.96 | $41k | 41,462 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -93 | $200.62 | $19k | 41,369 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -300 | $201.70 | $61k | 41,069 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -200 | $204.17 | $41k | 40,869 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -460 | $205.18 | $94k | 40,409 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -340 | $206.37 | $70k | 40,069 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -612 | $207.01 | $127k | 39,457 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -1,446 | $208.12 | $301k | 38,011 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -1,142 | $208.87 | $239k | 36,869 | Mar 6, 2026 |
| Mar 4, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 54,444 | Mar 6, 2026 |
Related signals
Other insiders at LIGAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.5M 5,000 shares | -14% | |
| 43Moderate | LIGAND PHARMACEUTICALS INC | Martine Zimmermann director | $342k 1,200 shares | -24% | |
| 33Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.4M 5,000 shares | -12% | |
| 47Moderate | LIGAND PHARMACEUTICALS INC | Octavio Espinoza Chief Financial Officer | $9.2M 31,641 shares | -53% | |
| 60Notable | LIGAND PHARMACEUTICALS INC | Jason Haas director | $2.1M 7,138 shares | -64% | |
| 25Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.4M 5,000 shares | -11% | |
| 10Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.6M 5,000 shares | -11% | |
| 34Weak | LIGAND PHARMACEUTICALS INC | Stephen L Sabba director | $545k 2,145 shares | -6% | |
| 60Notable | LIGAND PHARMACEUTICALS INC | Jason Haas director | $1.7M 6,461 shares | -56% | |
| 55Moderate | LIGAND PHARMACEUTICALS INC | Jason Aryeh director | $1.3M 5,000 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.